Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.7% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%.
The iShares Biotechnology ETF (IBB) was fractionally lower.
In corporate news, Ginkgo Bioworks (DNA) shares were falling past 7%. The company said Wednesday that Chief Financial Officer Mark Dmytruk will resign on May 30 to accept another opportunity.
Renovaro (RENB) said Thursday it has received a court ruling to expedite a trial this year related to its lawsuit against Predictive Oncology (POAI), seeking to enforce a contested merger agreement between the two biotech firms. Renovaro shares gained over 13%, while Predictive Oncology fell past 7%.
HOOKIPA Pharma (HOOK) shares jumped 13% after it said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences (GILD) for up to $10 million. Gilead shares were down nearly 1%.
Sanofi (SNY) has agreed to buy Vigil Neuroscience (VIGL) in a cash deal with an equity value of up to $600 million. Vigil shares soared 242% and Sanofi was down 0.6%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.